Scientists Find New Mechanism in the Development of Severe Inherited Disease
Scientists of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have shown that the genetic defect that causes Cockayne Syndrome affects a key function of the cell - the transcription of genes coding for ribosomal RNA.
Cockayne Syndrome is a recessively inherited disorder that belongs to a group of diseases in which defects in one of the numerous DNA repair systems lead to non-functioning proteins and, thus, to severe health impairments. These disorders also include, for example, Xeroderma pigmentosum and a type of hereditary bowel cancer.
However, symptoms of Cockayne Syndrome, which is a very rare disease, are particularly severe, including dwarfism, mental retardation, hearing and vision impairments; affected individuals have a characteristically formed small head, they age prematurely and die younger. The scale of these defects suggested that a dysfunctional DNA repair mechanism alone cannot be responsible for this whole range of impairments.
Cockayne Syndrome is characterized by a defect in the CSB protein, which is the main component of a particular DNA repair system. Research results of several working groups had already suggested that CSB is additionally involved in transcription, i.e. the conversion of DNA to RNA. However, the exact mechanism had remained unknown.
In each cell, various RNA types are responsible for specific tasks. Thus, the so-called rRNA is a key component of the ribosomes, the protein factories of the cell. A research group headed by Professor Dr. Ingrid Grummt of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) has now shown that CSB is pivotal in the production of rRNA molecules.
A basic prerequisite for the conversion of DNA to RNA is the accessibility of genes, which are normally tightly packed in the chromosome. Only if the genes are accessible can the enzyme RNA polymerase go about its work and synthesize new RNA molecules according to the DNA code. This is where CBS comes into play: It functions as an adapter between polymerase and the G9a protein, which acts like an icebreaker - making specific regions of the genetic material accessible for polymerase by chemically modifying the protein scaffold of the chromosome.
Without functioning CBS, the binding of polymerase I and G9a fails and the genes coding for rRNAs remain inaccessible for polymerase. The lack of rRNAs eventually leads to a standstill of protein synthesis in the cell - the most dramatic of imaginable consequences for an organism. This newly discovered function of CBS explains why a defect of this enzyme has such severe effects on the organism.
Xuejun Yuan, Weiijun Feng, Axel Imhof, Ingrid Grummt and Yonggang Zhou: Activation of RNA polymerase I transcription by Cockayne Syndrome group B (CSB) protein and histone methyltransferase G9a. Molecular Cell, August 19, 2007
The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful. The staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. Jointly with Heidelberg University Hospital, DKFZ has established the National Center for Tumor Diseases (NCT) Heidelberg, where promising approaches from cancer research are translated into the clinic. In the German Consortium for Translational Cancer Research (DKTK), one of six German Centers for Health Research, DKFZ maintains translational centers at seven university partnering sites. Combining excellent university hospitals with high-profile research at a Helmholtz Center is an important contribution to improving the chances of cancer patients. DKFZ is a member of the Helmholtz Association of National Research Centers, with ninety percent of its funding coming from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg.